LifeMD, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
LFMD$1.74-16.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
| LifeMD, Inc. · Non-controlling | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated · Treasury · Interest of Discontinued | |||||||||||
| Shares · Amount · Shares · Amount · Capital · Deficit · Stock · Total · Operations · Total | |||||||||||
| Balance, December 31, 2023 | 1,400,000 | $140 | 38,358,641 | $383,586 | $217,550,583 | $(215,335,665) | $(163,701) | $2,434,943 | $1,754,107 | $4,189,050 | |
| Stock compensation expense | - | - | 1,609,960 | 16,100 | 12,218,697 | - | - | 12,234,797 | - | 12,234,797 | |
| Stock issued for noncontingent consideration payments | - | - | 95,821 | 958 | 641,042 | - | - | 642,000 | - | 642,000 | |
| Exercise of stock options | - | - | 86,250 | 863 | 119,449 | - | - | 120,312 | - | 120,312 | |
| Cashless exercise of warrants | - | - | 1,630,458 | 16,305 | (16,305) | - | - | - | - | - | |
| Cashless exercise of stock options | - | - | 512,777 | 5,127 | (5,127) | - | - | - | - | - | |
| Series A Preferred Stock dividends | - | - | - | - | - | (3,106,250) | - | (3,106,250) | - | (3,106,250) | |
| Distributions to non-controlling interest of discontinued operations | - | - | - | - | - | - | - | - | (773,888) | (773,888) | |
| Net (loss) income | - | - | - | - | - | (21,409,016) | - | (21,409,016) | 548,875 | (20,860,141) | |
| Balance, December 31, 2024 | 1,400,000 | $140 | 42,293,907 | $422,939 | $230,508,339 | $(239,850,931) | $(163,701) | $(9,083,214) | $1,529,094 | $(7,554,120) | |
| Stock compensation expense | - | - | 2,358,181 | 23,582 | 10,472,739 | - | - | 10,496,321 | - | 10,496,321 | |
| Stock issued for debt conversion | - | - | 672,042 | 6,720 | 993,280 | - | - | 1,000,000 | - | 1,000,000 | |
| Stock issued for asset acquisition | - | - | 50,000 | 500 | 302,500 | - | - | 303,000 | - | 303,000 | |
| Exercise of stock options | - | - | 1,250 | 13 | 5,937 | - | - | 5,950 | - | 5,950 | |
| Exercise of warrants | - | - | 100,000 | 1,000 | 463,950 | - | - | 464,950 | - | 464,950 | |
| Sale of common stock under ATM, net | - | - | 762,990 | 7,630 | 8,714,087 | - | - | 8,721,717 | - | 8,721,717 | |
| Cashless exercise of stock options | - | - | 131,531 | 1,315 | (1,315) | - | - | - | - | - | |
| Cashless exercise of warrants | - | - | 390,115 | 3,901 | (3,901) | - | - | - | - | - | |
| Series A Preferred Stock dividends | - | - | - | - | - | (3,106,250) | - | (3,106,250) | - | (3,106,250) | |
| Distributions to non-controlling interest of discontinued operations | - | - | - | - | - | - | - | - | (773,658) | (773,658) | |
| Divestiture of non-controlling interest of discontinued operations | - | - | - | - | - | - | - | - | (2,021,121) | (2,021,121) | |
| Net income | - | - | - | - | - | 14,354,106 | - | 14,354,106 | 1,265,685 | 15,619,791 | |
| Balance, December 31, 2025 | 1,400,000 | $140 | 46,760,016 | $467,600 | $251,455,616 | $(228,603,075) | $(163,701) | $23,156,580 | $ | - | $23,156,580 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.